Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Bipolar Disorder (BD) is associated with progressive brain structural abnormalities.
• Lithium (Li+) is a primary treatment for acute and maintenance phases of BD.
• Li+ is postulated to be neuroprotective, similar to antipsychotics in schizophrenia.

Purpose of the Study:

• To investigate the neuroprotective mechanisms of Li+ in Bipolar Disorder.
• To determine if Li+-induced neuroprotection is linked to inhibition of specific molecular targets (IMPase, GSK3, PKC).
• To explore the correlation between Li+'s neuroprotective effects and its mood-stabilizing efficacy.

Main Methods:

• Review of existing literature on Li+ mechanisms in BD.
• Analysis of studies investigating Li+ effects on neurotrophic factors, inflammation, mitochondrial function, oxidative stress, autophagy, and apoptosis.
• Examination of research on Li+ inhibition of IMPase, GSK3, and PKC.

Main Results:

• Li+ exhibits neuroprotective properties by modulating nerve growth factors, inflammation, mitochondrial function, oxidative stress, autophagy, and apoptosis.
• The precise relationship between Li+ inhibition of IMPase, GSK3, and PKC and its neuroprotection in BD remains unclear.
• The correlation between these neuroprotective mechanisms and Li+'s clinical efficacy in mood stabilization requires further investigation.

Conclusions:

• Lithium (Li+) demonstrates significant neuroprotective potential in Bipolar Disorder (BD) through various cellular pathways.
• Further research is essential to elucidate the specific molecular targets mediating Li+'s neuroprotective effects and their link to clinical outcomes.
• Future precision medicine approaches may enhance BD diagnosis and treatment, potentially reducing the disorder's burden.